...
首页> 外文期刊>Heart >Is Mobitz type I atrioventricular block benign in adults?
【24h】

Is Mobitz type I atrioventricular block benign in adults?

机译:成人Mobitz I型房室传导阻滞是否良性?

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To assess the need for pacing in adults with chronic Mobitz type I second degree atrioventricular block (Mobitz I). Design: Prospective study. Setting: District general hospital. Patients: 147 subjects aged ≥ 20 years (age cohorts 20-44, 45-64, 65-79, and ≥ 80) with chronic Mobitz I without second degree Mobitz II or third degree (higher degree) block on entry, seen from 1968 to 1993 and followed up to 30 June 1997. Sixty four had organic heart disease. The presence of symptomatic bradycardia was defined as highly likely in 47 patients (class 1); probable in 14 (class 2); and absent in 86 (class 3). Interventions: Pacemakers were implanted in 90 patients for the following indications: symptoms in 74 and prophylaxis in 16. Main outcome measures: The main outcome measure was death, with conduction deterioration to higher degree block or symptomatic bradycardia the alternative measure. Results: Five year survival to death was reduced in unpaced patients relative to that expected for the normal population (overall mean (SD) 53.5 (6.7)% v 68.6%, p < 0.001; class 3, 54.4 (7.3)% v 70.1%, p < 0.001). Paced patients fared better than unpaced (overall (mean (SD) five year survival 76.3 (4.5)% v 53.5 (6.7)%, p = 0.0014; class 3, 87.2 (5.4)% v 54.4 (7.3)%, p = 0.020; and organic heart disease, 68.2 (7.6)% v 44.0 (9.9)%, p ≤ 0.0014). There were no deaths in the < 45 cohort. Survival to first outcome (main or alternative) was further reduced to 31.7 (5.0)% in 102 patients unpaced initially and 34.2 (5.7)% in class 3. Only the 20-44 cohort and patients with sinus arrhythmia had > 50% survival. Conclusion: Mobitz I block is not usually benign in patients ≥ 45 years of age. Pacemaker implantation should be considered, even in the absence of symptomatic bradycardia or organic heart disease.
机译:目的:评估成人Mobitz I型二级房室传导阻滞(Mobitz I)成人的起搏需求。设计:前瞻性研究。地点:地区综合医院。患者:从1968年开始,年龄≥20岁(年龄组20-44、45-64、65-79和≥80)的147名受试者患有慢性Mobitz I,进入时没有二级Mobitz II或三级(更高学位)随访到1993年,直至1997年6月30日。64例患有器质性心脏病。有症状的心动过缓的存在被定义为47例患者中的极有可能(1级)。可能在14(2级)中;并在86(第3类)中缺席。干预措施:为90例患者植入起搏器,以适应以下适应症:74例症状,16例预防症状。主要预后指标:主要预后指标为死亡,而传导性恶化至较高程度的传导阻滞或症状性心动过缓则为替代方法。结果:与正常人群的预期寿命相比,无节奏患者的五年死亡生存率降低了(总体平均(SD)53.5(6.7)%v 68.6%,p <0.001; 3级,54.4(7.3)%v 70.1% ,p <0.001)。起搏患者的情况好于无节奏患者(总体(平均(SD))五年生存率76.3(4.5)%v 53.5(6.7)%,p = 0.0014; 3级,87.2(5.4)%v 54.4(7.3)%,p = 0.020 ;以及器质性心脏病,分别为68.2(7.6)%v 44.0(9.9)%,p≤0.0014)。在45岁以下的人群中无死亡病例,至第一个结局(主要或替代)的生存率进一步降低至31.7(5.0)最初无节律的102例患者中的百分比为3%,在第3类中为34.2(5.7)%,只有20-44岁队列和窦性心律失常患者的存活率> 50%结论:Mobitz I阻滞通常在≥45岁的患者中不是良性的。即使没有症状性心动过缓或器质性心脏病,也应考虑使用起搏器植入。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号